Research

Work absence after breast cancer diagnosis: a population-based study

Mélanie Drolet, Elizabeth Maunsell, Myrto Mondor, Chantal Brisson, Jacques Brisson, Benoît Mâsse, Luc Deschênes

A longer version of this article is available at www.cmaj.ca/cgi/content/full/173/7/765.

Abstract

Background: Absence from work after breast cancer diagnosis may be part of the burden of disease for women with cancer, but little research has addressed this. We examined work absences of 4 weeks or more among women who had had breast cancer during the 3 years after diagnosis and compared their absences with those of women who had never had cancer.

Methods: Our 2 target study groups were women in Quebec 18–59 years of age who were working when they first received therapy for breast cancer between November 1996 and August 1997 and similarly aged women randomly selected from provincial health care files who had never had cancer and were working at the time of diagnosis in women who had cancer. We interviewed 646 women who had had breast cancer (73% of those eligible) and 890 women in the comparison group (51% of those eligible) by telephone 3 years after first diagnosis.

Results: One year after diagnosis, 85% (459/541) of breast cancer survivors who remained free of disease during the 3-year study period were absent from work for 4 weeks or more compared with 18% (156/881) of healthy women (geometric mean total duration 5.6 v. 1.7 months, \( p < 0.001 \)). By the third year, disease-free women were not absent more than women in the comparison group; however, more women who had experienced any new cancer event continued to be absent from work and to be absent from work for longer periods of time. Receiving adjuvant chemotherapy prolonged absence duration (9.5 v. 5.4 months among women not receiving chemotherapy). Compared with survivors belonging to a union, those who did not belong to a union (multivariate relative risk [RR] 7.54, 95% confidence interval [CI] 3.02–18.83) and those who were self-employed (RR 13.95, 95% CI 5.53–35.21) were more likely to report no work absence.

Interpretation: Most of the women with breast cancer took time off work (almost 6 months on average) after receiving the diagnosis. Three years after diagnosis, breast cancer survivors who remained disease-free — a large proportion of women with non-metastatic breast cancer — were not absent from work more often or for longer periods of time than other working women.

We compared absence from work during the 3 years after first diagnosis among breast cancer survivors and women who had never had cancer. The comparison group, which was composed of women subject to similar labour market forces, made it possible to determine the amount of absence from work that could be directly attributed to breast cancer and how long absence due to breast cancer continued after the initial treatment phase. We also investigated the characteristics of breast cancer survivors that were associated with duration of absence and with not being absent from work during the 3-year period after diagnosis.

Methods

The study participants and procedures have been described fully elsewhere, and a full description of the methods is available at www.cmaj.ca/cgi/content/full/173/7/765.

We used the Quebec Tumour Registry to identify consecutive women 18–59 years of age in whom breast cancer was newly diagnosed between November 1996 and August 1997. To assemble a population-based comparison group, we selected from the files of the Régie de l’assurance maladie du Québec (RAMQ) a random
sample of women in the same age range who were living in the province of Quebec at the same time that breast cancer was diagnosed in the patients but who had never had cancer. All breast cancer survivors had to be employed in the month of diagnosis, and women in the comparison group had to be employed during the same month (± 1) that breast cancer was diagnosed among survivors.

The follow-up period began for both breast cancer survivors and women in the comparison group in the month and year that breast cancer was first diagnosed in the survivor group. The follow-up period ended at the time of the interview 3 years after diagnosis. The mean duration of follow-up was comparable in both groups (41 ± 2 months).

When possible, outcomes were assessed separately for survivors who remained disease-free during follow-up and for women who experienced any new breast cancer event (local, regional or distant recurrence, or a new primary breast cancer in the other breast) in the same period. Generalized linear models were used for analysis of continuous variables. Generalized linear models with a log link and binomial distribution for errors were used for the analysis of categorical data. This analysis is similar to logistic regression but provides a true relative risk instead of an odds ratio.7

Total duration of absence was calculated by summing the duration of all absences from work of 4 weeks or more, including those taken for vacation. Periods without work because of unemployment were not considered as absence from work. Because the number and duration of absences were not normally distributed, analyses were performed on log-transformed data, and least-square means were transformed back to the original scale. Thus, geometric means are presented. The confounding effects of age, belonging to a union, being self-employed, living with a partner, years of employment at the job held at the start of follow-up, personal income, number of hours worked per week, type of job, comorbid conditions, and total duration of employment during follow-up were evaluated. If the crude and adjusted estimates differed by more than 10%, the factor was considered a confounder and included in the model.

This study was approved by the Commission d’accès à l’information du Québec and the Ethics Committee of the Hôpital du Saint-Sacrement.

**Results**

We sent letters about the study to 1504 breast cancer survivors and 2921 women in the comparison group who were eligible on the basis of age. We calculated that 885 of these survivors and 1745 of the women in the comparison group who were eligible for the study. Baseline characteristics were similar for the 2 study groups (Table 1).

Survivors worked a mean of 35 (standard deviation [SD] 13) hours per week, whereas women in the comparison group worked a mean of 34 (SD 11) hours per week. More than 90% of survivors and women in the comparison group reported having no activity-limiting medical problems during the study period. The mean delay between surgery and the start of adjuvant radiotherapy or chemotherapy was 5.5 (SD 3.8) weeks for women who had chemotherapy only or chemotherapy and radiotherapy and 12.3 (SD 7.5) weeks for women who received radiotherapy only (data not shown).

Of disease-free survivors, 85% reported at least 1 absence from work of 4 weeks or more for any reason during the first year after diagnosis, with a geometric mean total duration of 5.6 months (Table 2). In contrast, 18% of women who experienced any new breast cancer event (local, regional or distant recurrence, or a new primary breast cancer in the other breast) in the same period.

| Disease-free survivors | Survivors with NBCE | Comparison women |
|------------------------|---------------------|------------------|
| Characteristic         | No. (%)† of participants |
| Sociodemographic       |                     |
| Age, mean, yr (SD)     | 47 (7)              | 46 (7)           | 45 (8)  |
| Education              |                     |
| High school or less    | 248 (43)            | 31 (39)          | 391 (44) |
| Collegial level        | 151 (27)            | 24 (30)          | re (24)  |
| Some university or more| 168 (30)            | 24 (30)          | 253 (28) |
| Lives with a partner   | 404 (71)            | 53 (67)          | 685 (77) |
| Personal income, $     | n = 553             | n = 78           | n = 868  |
| < 30 000               | 337 (60)            | 50 (63)          | 576 (64) |
| 30 000–49 999          | 164 (29)            | 20 (26)          | 224 (26) |
| ≥ 50 000               | 52 (9)              | 8 (10)           | 68 (8)   |
| Work                   |                     |
| Part-time job (< 30 hr/wk) | 132 (24)           | 16 (20)          | 237 (27) |
| White-collar job       | 450 (79)            | 39 (5)           | 691 (78) |
| Self-employed          | 86 (15)             | 17 (21)          | 141 (16) |
| Union member‡          | 247 (51)            | 39 (63)          | 346 (46) |
| Disease and treatments  |                     |
| Invaded axillary nodes at diagnosis, no. |     |
| 0                      | 308 (63)            | 35 (50)          | 308 (63) |
| ≥ 1                    | 169 (35)            | 34 (49)          | 169 (35) |
| Unknown                | 10 (2)              | 1 (1)            | 10 (2)   |
| First treatment undergone |                  |
| Breast surgery or axillary dissection or both | 537 (95)      | 74 (94)          | 537 (95) |
| Neo-adjuvant chemotherapy | 30 (5)             | 5 (6)            | 30 (5)   |
| Partial mastectomy     | 476 (84)            | 57 (72)          | 476 (84) |
| Axillary dissection    | 487 (86)            | 71 (90)          | 487 (86) |
| Radiotherapy           | 467 (82)            | 57 (72)          | 467 (82) |
| Chemotherapy           | 320 (56)            | 47 (59)          | 320 (56) |
| Hormone therapy        | 281 (50)            | 29 (37)          | 281 (50) |
| Adjuvant treatments undergone,§ no. | 0                   |
| 0                      | 25 (4)              | 7 (9)            | 25 (4)   |
| 1                      | 144 (25)            | 27 (34)          | 144 (25) |
| 2                      | 270 (47)            | 29 (37)          | 270 (47) |
| 3                      | 128 (23)            | 16 (20)          | 128 (23) |

Note: NBCE = new breast cancer event during follow-up, SD = standard deviation.
*The full-text version of this table is available online at www.cmaj.ca/cgi/content/full/173/7/765.
†Percentages may not equal 100% because of rounding.
‡Percentages calculated after exclusion of self-employed women.
§Chemotherapy, radiotherapy and hormone therapy.
(p < 0.001) of women in the comparison group reported at least 1 absence during the same period, with a mean total duration of 1.7 months (p < 0.001). In the third year after diagnosis, disease-free survivors were no more likely to have been off work than women in the comparison group. Among survivors with new cancer events, absences during the first year were comparable with those of disease-free survivors, but the duration of their absences remained longer than those of women who had never had cancer through to the end of follow-up. Absence specifically because of breast cancer during the 3-year follow-up was, on average, longer among survivors with new breast cancer events than among disease-free survivors (9.8 v. 5.9 months) (data not shown). These crude results were not substantially changed by adjustment for potential confounders.

Among survivors, 81% began their first absence after diagnosis — the one most likely to be related to breast cancer — within 1 month. This first absence lasted less than 4 months for 26% of the women, 4–6 months for 24%, 7–12 months for 37% and 13 months or longer for 12%.

In the multivariate analysis, age less than 50 years, belonging to a union, chemotherapy, new cancer events during follow-up and physician advising absence from work all significantly increased absence duration for any reason (see Table 3 in the online version at www.cmaj.ca/cgi/content/full/173/7/765). Receiving chemotherapy and the number of adjuvant treatments received had the greatest influence on duration. Characteristics predicting absence duration for cancer only were similar.

Two percent of women belonging to a union, 15% of those who did not belong to a union and 34% of self-employed workers reported no absence from work during follow-up. Compared with women belonging to a union, those who did not belong to a union (multivariate relative risk [RR] 7.54, 95% confidence interval [CI] 3.02–18.83) and those who were self-employed (RR 13.95, 95% CI 5.53–52.21) were more likely to report no absence from work (Table 3). Having a white-collar job and not receiving a recommendation to take time off work from the physician also increased the likelihood of reporting no absence from work. Not having radiotherapy and no invaded axillary nodes were borderline predictors of reporting no absence from work (p = 0.08). Characteristics predicting no absence because of cancer were similar.

**Interpretation**

Most breast cancer patients took time off work in the first year after diagnosis, and the time taken was, on average, almost 6 months. This represents a considerable excess attributable to disease when compared with similarly aged women who had never had cancer. In contrast to previous studies that reported only percentages of breast cancer patients at work or that had a shorter follow-up,5,6,8 we were able to show that, among survivors who remained free of disease, the excess of absence had considerably declined by year 2, and, by year 3, these women were not absent from work more often or for longer periods than other working women in Quebec. However, for patients who experienced new cancer events, overall absences remained in excess compared with healthy women throughout the 3-year follow-up. Women who belonged to a union or who had a blue-collar or service industry job were those most likely to be absent for some period. For those taking time off, chemotherapy in particular, multimodal adjuvant treatment and belonging to a union generally increased absence duration.

Because this study is population-based, we collected information about women from all socioeconomic strata and

---

**Table 2: Number and total duration of absences from work of 4 weeks or more among breast cancer survivors and women in the comparison group**

| Time period | Disease-free survivors | Survivors with NBCE | Comparison women |
|-------------|------------------------|---------------------|-----------------|
|             | n/N (%)† | Absences, mean* (95% CI) | n/N (%)† | Absences, mean* (95% CI) | n/N (%)† | Absences, mean* (95% CI) |
|             | Number | Duration, mo | Number | Duration, mo | Number | Duration, mo |
| Year 1      | 459/541 (85)% | 1.1 (1.0–1.1) | 5.6 (5.3–6.0) | 63/77 (83)% | 1.1 (1.0–1.1) | 5.9 (5.0–7.1) | 156881 (18) | 1.0 (0.9–1.1) | 1.7 (1.6–1.9) |
| Year 2      | 14/502 (29)% | 1.1 (1.0–1.1) | 2.7 (2.4–3.0) | 29/75 (39)% | 1.1 (1.0–1.2) | 3.7 (2.8–4.8) | 144820 (18) | 1.0 (1.0–1.1) | 1.9 (1.6–2.1) |
| Year 3      | 94/492 (19) | 1.1 (1.0–1.1) | 2.1 (1.9–2.4) | 34/68 (50)% | 1.1 (1.0–1.1) | 4.1 (3.2–5.2) | 150804 (19) | 1.1 (1.0–1.1) | 1.9 (1.7–2.2) |
| Total       | 469/548 (86)% | 1.3 (1.2–1.4) | 6.8 (6.4–7.3) | 67/77 (87)% | 1.7 (1.5–2.0) | 10.2 (8.4–12.4) | 281886 (34) | 1.6 (1.5–1.7) | 3.4 (3.1–3.7) |

Note: NBCE = new breast cancer event, CI = confidence interval.

*Geometric means.
†Percentages of women reporting an absence among women who were employed during the period shown.
‡Women in the comparison group and 21 survivors were excluded from the analysis because they left the job they had held before diagnosis at the time of diagnosis (or similar period for comparison women) and never returned at work.
§The proportion of survivors is statistically significant (p ≤ 0.001) compared with women in the comparison group (χ² test).
from urban, suburban and rural areas. As well, we have previously shown that study participants were very similar to Quebec women generally in terms of geographic distribution and key work characteristics. The course of treatment for cancer patients in this study closely resembled that of other complete series of Quebec women we have identified.

Table 3: Characteristics of all breast cancer patients predicting the risk of reporting no absence from work of 4 weeks or more for any reason or because of cancer during the study period

| Characteristic                                      | No absence for any reason (75/611);* relative risk (95% CI) | No absence due to cancer (138/611); relative risk (95% CI) |
|----------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                    | Univariate Multivariate†                                    | Univariate Multivariate†                                    |
| Age range, yr                                      |                                                            |                                                            |
| 18–39                                              | 1.00                                                       | 1.00                                                       |
| 40–49                                              | 1.07 (0.53–2.18)                                           | 0.92 (0.59–1.44)                                           |
| 50–59                                              | 1.45 (0.73–2.88)                                           | 1.10 (0.71–1.72)                                           |
| Personal income, $                                 |                                                            |                                                            |
| < 30 000                                           | 1.21 (0.58–2.53)                                           | 1.28 (0.75–2.19)                                           |
| 30 000–49 999                                      | 0.56 (0.23–1.35)                                           | 0.76 (0.41–1.40)                                           |
| ≥ 50 000                                           | 1.00                                                       | 1.00                                                       |
| Education                                          |                                                            |                                                            |
| High school or less                                | 1.62 (0.92–2.84)                                           | 1.55 (1.06–2.26)                                           |
| Collegial level                                    | 1.67 (0.92–3.03)                                           | 1.36 (0.89–2.06)                                           |
| Some university or more                            | 1.00                                                       | 1.00                                                       |
| Union membership                                   |                                                            |                                                            |
| Yes                                                | 1.00                                                       | 1.00                                                       |
| No                                                 | 8.16 (3.25–20.45)                                          | 7.54 (3.02–18.83)                                          |
| No; self-employed                                  | 18.77 (7.54–46.69)                                         | 13.95 (5.53–35.21)                                         |
| Type of job                                        |                                                            |                                                            |
| White-collar                                       | 1.61 (0.85–3.03)                                           | 0.93 (0.65–1.33)                                           |
| Blue-collar or service                             | 2.59 (1.42–4.70)                                           | 1.46 (1.06–2.02)                                           |
| Duration of employment at the job held at start of follow-up, yr |                                                            |                                                            |
| 0–4                                                | 2.64 (1.46–4.78)                                           | 1.88 (1.26–2.80)                                           |
| 5–14                                               | 1.79 (0.97–3.30)                                           | 1.59 (1.07–2.36)                                           |
| 15–39                                              | 1.00                                                       | 1.00                                                       |
| Time working, hr/wk                                |                                                            |                                                            |
| Part time or < 30                                  | 1.90 (1.22–2.93)                                           | 1.58 (1.16–2.15)                                           |
| Full time or ≥ 30                                  | 1.00                                                       | 1.00                                                       |
| Adjuvant radiotherapy                              |                                                            |                                                            |
| No                                                 | 1.25 (0.76–2.06)                                           | 1.40 (0.96–2.03)                                           |
| Yes                                                | 1.00                                                       | 0.99 (0.68–1.44)                                           |
| Adjuvant chemotherapy                              |                                                            |                                                            |
| No                                                 | 1.27 (0.83–1.94)                                           | 1.39 (1.04–1.87)                                           |
| Yes                                                | 1.00                                                       | 1.00                                                       |
| Adjuvant hormone therapy                           |                                                            |                                                            |
| No                                                 | 1.16 (0.76–1.78)                                           | 1.30 (0.96–1.75)                                           |
| Yes                                                | 1.00                                                       | 1.00                                                       |
| Adjuvant treatments undergone,‡ no.                |                                                            |                                                            |
| 0                                                  | 2.25 (1.05–4.84)                                           | 2.11 (1.15–3.88)                                           |
| 1                                                  | 1.10 (0.59–2.05)                                           | 1.50 (0.94–2.38)                                           |
| 2                                                  | 0.97 (0.54–1.73)                                           | 1.34 (0.87–2.09)                                           |
| 3                                                  | 1.00                                                       | 1.00                                                       |
| Invaded axillary nodes at diagnosis, no.           |                                                            |                                                            |
| None, no axillary dissection                        | 1.41 (0.85–2.32)                                           | 1.52 (0.94–2.46)                                           |
| ≥ 1 node                                           | 1.00                                                       | 1.00                                                       |
| New breast cancer event after first diagnosis       |                                                            |                                                            |
| No                                                 | 0.94 (0.50–1.74)                                           | 0.90 (0.59–1.38)                                           |
| Yes                                                | 1.00                                                       | 1.00                                                       |
| Physician advised work absence                      |                                                            |                                                            |
| No                                                 | 4.20 (2.66–6.63)                                           | 2.81 (1.77–4.48)                                           |
| Yes                                                | 1.00                                                       | 2.63 (1.96–3.53)                                           |

Note: CI = confidence interval.

*The analysis excluded 21 women who stopped working at diagnosis and never returned and 14 women who stopped working after diagnosis and start working at a different job more than 1 year later.

†The multivariate model included only variables that remained statistically significant predictors when included in a single model.

‡Of radiotherapy, chemotherapy and hormone therapy.
at diagnosis. Thus, our results likely represent work absence among all working women with breast cancer who undergo its multimodal treatment.

Because absences were assessed retrospectively, we took several steps to minimize possible recall bias. We used evidence-based interview techniques to help participants recall events chronologically. Since information bias due to memory problems is more of a problem for reporting frequent events, we asked about absences of 4 consecutive weeks or more, which are not frequent and thus easier to remember. Although women in the comparison group did not have a breast cancer diagnosis to index their recall of absences, the events that caused absences of 4 weeks or more (vacation, illness, work conflicts, lockouts and deferred salary leave) were all memorable and thus probably as easy to remember for them as for breast cancer survivors. Apart from the final questions for patients only, interviews were worded identically for both groups in the study. Finally, evidence that we were successful in measuring absences comes from the stability of both the percentages of women in the comparison group reporting absences of 4 weeks or more and the duration of those absences for each year of follow-up. On a population level, it is reasonable to assume that events resulting in such absences are probably evenly distributed from 1 year to the next.

Although the positive and negative consequences of being absent from work on health, quality of life and work situation remain to be assessed, our results suggest some hardship in relation to job absence for certain breast cancer survivors. Being able to take time off work for breast cancer treatment does not appear to be an option equally available to all working women with this disease. Self-employed women or those not belonging to a union were much less likely to take time off work for initial treatments, even though their treatments resembled those of women who did take time off. These women may not feel able to take time off because their income decreases or stops when they are absent. Even some who do take time off work may experience financial burden because of the length of absence from work. For 74% of survivors, absence durations exceeded the 15-week federal employment insurance available during periods of illness, although an unknown proportion of women may have had access to additional disability insurance. Nonetheless, given that salary loss represents the greatest and most worrisome financial cost of breast cancer for some women, work absence likely represents a negative aspect of the cancer experience.

This article has been peer reviewed.

From the Unité de recherche en santé des populations, Centre de recherche du Centre Hospitalier Affilié Universitaire de Québec (Drolet, Maunsell, Mondor, Brisson C, Brisson J), the Université Laval (Maunsell, Brisson C, Brisson J), the Centre des maladies du sein Deschênes-Fabia, Hôpital du Saint-Sacrement, Québec, Qué. (Maunsell, Brisson J, Deschênes), and the Fred Hutchinson Cancer Research Center, Seattle, Wash. (Masse)

Competing interests: None declared.

Contributors: Elizabeth Maunsell, as the principal investigator, had overall responsibility for all aspects of the study, including its conception and design, the acquisition, analysis and interpretation of data and drafting the manuscript. Mélanie Drolet contributed to the acquisition, analysis and interpretation of data and drafted the manuscript. Myrto Mondor conducted the analysis. Jacques Brisson, Chantal Brisson, Benoît Masse and Luc Deschênes contributed to the conception and design of the study and to the interpretation of data. All of the authors revised the manuscript critically for important intellectual content and approved the final version.

Acknowledgements: Financial support for this study was provided by research grants from the Canadian Breast Cancer Research Alliance and the Fondation Québecoise du Cancer. Elizabeth Maunsell and Chantal Brisson were National Health Research and Development Program National Health Research Scholars at the time this work was originally planned and funded, and are (E. Maunsell) or were (C. Brisson) Investigators of the Canadian Institutes of Health Research. Mélanie Drolet holds a PhD Fellowship Award from the Fonds de recherche en santé du Québec.

We thank Ninon Bourque (deceased), Director General of Communications, Department of Fisheries and Oceans, Ottawa and founding member of the Canadian Breast Cancer Network, for her invaluable contribution as part of the investigator group that planned and obtained funding for this study. We also thank the women who so generously gave their time to participate in this research.

References

1. Maunsell E, Drolet M, Brisson J, Brisson C, Masse B, Deschênes L. Work situation after breast cancer: results from a population-based study. J Natl Cancer Inst 2004;96:1813-22.
2. Bradley CJ, Bednarek HL, Neumark D. Breast cancer and women’s labor supply. Health Serv Res 2002;37:1109-28.
3. Bloom JR, Stewart SL, Chang S, Banks PJ. Then and now: quality of life of young breast cancer survivors. Psychonosymology 2004;11:147-60.
4. Ganz PA, Ciacarelli A, Fred C, Kahn B, Polinsky ML, Petersen L. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 1996;18:183-99.
5. Bushunow PW, Sun Y, Raubertas RF, Rosenhall S. Adjuvant chemotherapy does not affect employment in patients with early-stage breast cancer. J Gen Intern Med 1995;10:73-6.
6. Satatiano PW, De Lorenzo GN. The likelihood of returning to work after breast cancer. Public Health Rep 1996;111:236-41.
7. Spelten ER, Sprangers MA, Verbeek JH. Factors reported to influence the return to work of cancer survivors: a literature review. Psychonosymology 2002;11:124-31.
8. Spelten ER, Verbeek JH, Utterhove AH, Annik AC, van der Leij J, de Renike TM, et al. Cancer, fatigue and the return of patients to work: a prospective cohort study. Eur J Cancer 2003;39:1562-7.
9. Commission des normes du travail du Québec. Absence pour cause de maladie ou d’accident. Available: www.cnt.gov.qc.ca/fr/normes/maladie.asp (accessed 1 Sept 2005).
10. Lauzier S, Maunsell E, De Koninck M, Drolet M, Mebert-Croteau N, Robert J. Conceptualization and sources of costs from breast cancer: findings from patients and caregivers focus group. Psychonosymology 2005;14:351-60.
11. Skov T, Deiddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol 1998;27:91-5.
12. Maunsell E, Brisson J, Deschênes L, Frasure-Smith N. Randomized trial of a psychologic distress screening program after breast cancer: effects on quality of life. J Clin Oncol 1996;14:2747-55.
13. Dorval M, Guay S, Mondor M, Masse B, Falaradeau M, Robidoux A, et al. Couples who get closer after breast cancer: frequency and predictors in a prospective investigation. J Clin Oncol 2005;23:3588-96.
14. Fossey W. Constructing questions for interviews and questionnaires. Cambridge (UK): Cambridge University Press; 1993.
15. Sudman S, Bradburn N, Schwarz N. Thinking about answers: the application of cognitive processes to survey methodology. San Francisco: Jossey-Bass Publishers; 1996.